TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine: review decision - April 2015
The Institute was proposing that the guidance should be transferred to the ‘static guidance list’.
Responses received from stakeholders during the consultation (available to view in Appendix A) suggested that this may not be the most appropriate course of action.
As the Institute is currently undertaking a surveillance review of the clinical guideline for dementia (CG42), it was deemed appropriate to pause the consideration of a review of TA217 until the surveillance of CG42 was complete.
Now that the decision has been made to update CG42, the Institute’s Guidance Executive has decided that:
- Recommendations 1.1 and 1.2 from TA217 should move to the static list of technology appraisals, as originally proposed, and
- Recommendation 1.3 from TA217 should be considered for review in the update of CG42
- Recommendations 1.4, 1.5 and 1.6 should move to the static list of technology appraisals, as originally proposed.
Should the forthcoming clinical guideline update recommendation 1.3, then this recommendation would be withdrawn once the guideline is published.
This page was last updated: 28 April 2015